Arachidonic Acid Metabolites and the Kidney in Cirrhosis

Ascites and Renal Dysfunction in Liver Disease: Pathogenesis, Diagnosis, and Treatment: Second Edition

Volumn , Issue , 2007, Pages 84-104

  Ippolito, Silvia ^a   Moore, Kevin P ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Arachidonic acid metabolites; Cirrhosis; Eicosanoids; Hydroxyeicosatetraenoic acids (HETEs); Linoleic acid

Indexed keywords

EID: 84889406559     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470987476.ch7     Document Type: Chapter

References (139)

1. Robinson JR. Refl ections on renal function. Oxford: Blackwell, 1988.
2. Schlondorff D, Aynedjian HS, Satriano JA, Bank N. In vivo demonstration of glomerular PGE2 responses to physiological manipulations and experimental agents. Am J Physiol 1987; 252:F717-F723.
3. Arieff AI, Chidsey CA. Renal function in cirrhosis and the effects of prostaglandin A1. Am J Med 1974; 56:695-703.
4. Boyer TD, Reynolds TB. Prostaglandin insuffi ciency: a role in the hepatorenal syndrome? Gastroenterology 1976; 899: Abstract.
5. Boyer TD, Zia P, Reynolds TB. Effect of indomethacin and prostaglandin A1 on renal function and plasma renin activity in alcoholic liver disease. Gastroenterology 1979; 77:215-22.
6. Zia P, Zipser R, Speckart P, Horton R. The measurement of urinary prostaglandin E in normal subjects and in highrenin states. J Lab Clin Med 1978; 92:415-22.
7. Zipser R, Hoefs J, Speckart P et al. Prostaglandins: modulators of renal function and pressor resistance in chronic liver disease. J Clin Endocrinol Metab 1979; 48:895-900.
8. Breyer MD, Harris RC. Cyclooxygenase 2 and the kidney. Curr Opin Nephrol Hypertens 2001; 10:89-98.
9. Graupera M, Garcia-Pagan JC, Abraldes JG et al. Cyclooxygenase-derived products modulate the increased intrahepatic resistance of cirrhotic rat livers. Hepatology 2003; 37:172-81.
10. Zhonghua Qi, Chuan-Ming Hao, Robert I et al. Opposite effects of cyclooxygenase-1 and-2 activity on the pressor response to angiotensin II. J Clin Invest 2002; 110:61-9.
11. Balmforth AJ, Shepherd FH, Warburton P, Ball SG. Evidence of an important and direct role for protein kinase C in agonist-induced phosphorylation leading to desensitization of the angiotensin AT1A receptor. Br J Pharmacol 1997; 122:1469-77.
12. Siragy HM, Senbonmatsu T, Ichiki T et al. Increased renal vasodilator prostanoids prevent hypertension in mice lacking the angiotensin subtype-2 receptor. J Clin Invest 1999; 104:181-8.
13. Tsutsumi Y, Matsubara H, Masaki H et al. Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation. J Clin Invest 1999; 104:925-35.
14. Arroyo V, Planas R, Gaya J et al. Sympathetic nervous activity, renin-angiotensin system and renal excretion of prostaglandin E2 in cirrhosis. Relationship to functional renal failure and sodium and water excretion. Eur J Clin Invest 1983; 13:271-8.
15. Arroyo V, Ginès P, Rimola A, Gaya J. Renal function abnormalities, prostaglandins, and effects of non steroidal anti-infl ammatory drugs in cirrhosis with ascites. An overview with emphasis on pathogenesis. Am J Med 1986; 81:104-22.
16. Dunn MJ. Role of eicosanoids in the control of the renal function in severe hepatic disease. Gastroenterology 1984; 87:1392-5.
17. Lopez-Parra M, Claria J, Planaguma A et al. Cyclooxygenase-1 derived prostaglandins are involved in the maintenance of renal function in rats with cirrhosis and ascites. Br J Pharmacol 2002; 135:891-900.
18. Katayama S, Attallah AA, Sthal RA et al. Mechanism of furosemide-induced natriuresis by direct stimulation of renal prostaglandin E2. Am J Physiol 1984; 247:F555-F561.
19. Bosch-Marce M, Claria J, Titos E et al. Selective inhibition of cyclooxygenase-2 spares renal function and prostaglandin synthesis in cirrhotic rats with ascites. Gastroenterology 1999; 116:1167-75.
20. Badr KF, Jacobson H. Arachidonic acid metabolites and the kidney. In: Brenner BM, Rector FC, eds. The Kidney, 4th edn. Philadelphia: WB Saunders, 1991; 584-622.
21. Brady HR, Lamas S, Papayianni A et al. Lipoxygenase product formation and cell adhesion during neutrophil-glomerular endothelial cell interaction. Am J Physiol 1995; 268:F1-F12.
22. Badr KF, Baylis C, Pfeffer JM et al. Renal and systemic hemodynamic responses to intravenous infusion of leukotriene C4 in the rat. Circ Res 1984; 54:492-9.
23. Badr KF, Schreiner GF, Wasserman M, Ichikawa I. Preservation of the glomerular capillary ultrafi ltration coeffi cient during rat nephrotoxic serum nephritis by a specifi c leukotriene D4 receptor antagonist. J Clin Invest 1988; 81:1702-9.
24. Badr KF, DeBoer DK, Schwartzberg M, Serhan CN. Lipoxin A4 antagonizes cellular and in vivo actions of leukotriene D4 in rat glomerular mesangial cells: evidence for competition at a common receptor. Proc Natl Acad Sci USA 1989; 86:3438-42.
25. Terada Y, Tomita K, Yoshiyama N et al. Leukotriene D4 inhibits atrial natriuretic factor-dependent cGMP production in rat glomerulus. Am J Physiol 1989; 256:F95-F99.
26. Moore KP, Taylor GW, Maltby NH et al. Increased production of cysteinyl leukotrienes in hepatorenal syndrome. J Hepatol 1990; 11:263-71.
27. Moore KP, Taylor GW, Gove C et al. Synthesis and metabolism of cysteinyl leukotrienes by the isolated pig kidney. Kidney Int 1992; 41:1543-8.
28. Sraer J, Rigaud M, Bens M et al. Metabolism of arachidonic acid via the lipoxygenase pathway in human and murine glomeruli. J Biol Chem 1983; 258:4325-30.
29. Stern N, Yanagawa N, Saito F et al. Potential role of 12 hydroxyeicosatetraenoic acid in angiotensin II-induced calcium signal in rat glomerulosa cells. Endocrinology 1993; 133:843-7.
30. Rimola A, Ginès P, Arroyo V et al. Urinary excretion of 6-keto-prostaglandin F1a, thromboxane B2 and prostaglandin E2 in cirrhosis with ascites. J Hepatol 1986; 3:111-17.
31. Miyamori I, FitzGerald GA, Brown MJ, Lewis PJ. Prostacyclin stimulates the renin angiotensin aldosterone system in man. J Clin Endocrinol Metab 1979; 49:943-4.
32. Breyer MD, Jacobson HR, Breyer RM. Functional and molecular aspects of renal prostaglandin receptors. J Am Soc Nephrol 1996; 7:8-17.
33. Breyer MD, Davis L, Jacobson HR, Breyer RM. Differential localization of prostaglandin E receptor subtypes in human kidney. Am J Physiol 1996; 270:F912-F918.
34. Hebert RL, Jacobson HR, Breyer MD. PGE2 inhibits AVPinduced water fl ow in cortical collecting ducts by protein kinase C activation. Am J Physiol 1990; 259:F318-F325.
35. Mirouze D, Zipser RD, Reynolds TB. Effect of inhibitors of prostaglandin synthesis on induced diuresis in cirrhosis. Hepatology 1983; 3:50-5.
36. Nadler J, Zipser RD, Coleman R, Horton R. Stimulation of renal prostaglandins by pressor hormones in man: comparison of prostaglandin E2 and prostacyclin (6 keto prostaglandin F1). J Clin Endocrinol Metab 1983; 56: 1260-2.
37. Zusman RM, Keiser HR. Prostaglandin biosynthesis by rabbit renomedullary interstitial cells in tissue culture. Stimulation by angiotensin II, bradykinin, and arginine vasopressin. J Clin Invest 1977; 60:215-23.
38. Gerber JG, Nies S. Interaction between furosemide induced renal vasodilatation and the prostaglandin system. Prostaglandin Med 1981; 6:135-45.
39. Planas R, Arroyo V, Rimola A et al. Acetylsalicylic acid suppresses the renal hemodynamic effect and reduces the diuretic action of furosemide in cirrhosis with ascites. Gastroenterology 1983; 84:247-52.
40. Quiroga J, Zozaya JM, Labarga P et al. Renal prostacyclin infl uences renal function in non-azotemic cirrhotic patients treated with furosemide. J Hepatol 1991; 12:170-5.
41. Pérez-Ayuso RM, Arroyo V, Camps J et al. Evidence that renal prostaglandins are involved in renal water metabolism in cirrhosis. Kidney Int 1984; 26:72-80.
42. Grantham JJ, Orloff J. Effect of prostaglandin E1 on the permeability response of the isolated collecting tubule to vasopressin, adenosine 39,59-monophosphate, and theophylline. J Clin Invest 1968; 47:1154-61.
43. Noland TD, Carter CE, Jacobson HR, Breyer MD. PGE2 regulates cAMP production in cultured rabbit CCD cells: evidence for dual inhibitory mechanisms. Am J Physiol 1992; 263:C1208-C1215.
44. Reznick RK, Langer B, Taylor BR et al. Hyponatremia and arginine vasopressin secretion in patients with refractory hepatic ascites undergoing peritoneovenous shunting. Gastroenterology 1983; 84:713-18.
45. Hsia H-C, Lin H-C, Tsai Y-T et al. The effects of chronic administration of indomethacin and misoprostol on renal function in cirrhotic patients with and without ascites. Scand J Gastroenterol 1995; 30:1195-9.
46. Schlondorff D. The glomerular mesangial cell: an expanding role for a specialized pericyte. FASEB J 1987; 1:272-81.
47. Scharschmidt LA, Dunn MJ. Prostaglandin synthesis by rat glomerular mesangial cells in culture. J Clin Invest 1983; 71:1756-65.
48. Ardaillou N, Nivez MP, Striker G, Ardaillou R. Prostaglandin synthesis by human glomerular cells in culture. Prostaglandins 1983; 26773-84.
49. Scharschmidt LA, Douglas JG, Dunn MJ. Angiotensin II and eicosanoids in the control of glomerular size in the rat and human. Am J Physiol 1986; 250:F348-F356.
50. Dunn MJ, Scharschmidt LA. Prostaglandins modulate the glomerular actions of angiotensin II. Kidney Int 1987; 31: S-95-S-101.
51. Galler M, Backenroth R, Folkert VM, Schlondorff D. Effect of converting enzyme inhibitors on prostaglandin synthesis by whole glomeruli and aortic strips from rats. J Pharmacol Exp Ther 1982; 220:23-8.
52. Bayliss C, Brenner BM. Modulation by prostaglandin synthesis inhibitors of the action of exogenous angiotensin II on glomerular ultrafi ltration in the rat. Circ Res 1978; 43:889-98.
53. Pinilla JM, Alberola A, Gonzales JD et al. Role of prostaglandins on the renal effects of angiotensin and interstitial pressure during volume expansion. Am J Physiol 1993; 265:R1469-R1474.
54. Fiksen-Olsen MJ, Romero JC. Renal effects of prostaglandin inhibition during increases in renal venous pressure. Am J Physiol 1991; 260:525-4.
55. Mullane JR, Gliedman ML. Elevation of the pressure of the abdominal inferior vena cava as a cause of the hepatorenal syndrome in cirrhosis. Surgery 1966; 59:1135-46.
56. Fitzgerald GA, Brash AR, Falardeau P, Oates JA. Estimated rate of prostacyclin secretion into the circulation of normal man. J Clin Invest 1981; 68:1272-6.
57. Zipser RD, Martin K. Urinary excretion of arterial blood prostaglandins and thromboxanes in man. Am J Physiol 1982; 242:171-7.
58. Brash AR, Jackson EK, Saggese CA et al. Metabolic disposition of prostacyclin in humans. J Pharmacol Exp Ther 1983; 226:78-87.
59. Rosenkranz B, Fischer B, Reimann I et al. Identifi cation of the major metabolite of prostacyclin and 6-keto PGF1 in man. Biochem Biophys Acta 1980; 619:207-13.
60. Guarner F, Guarner C, Prieto J et al. Increased synthesis of systemic prostacyclin in cirrhotic patients. Gastroenterology 1986; 90:687-94.
61. Moore K, Ward PS, Taylor GW, Williams R. Systemic and renal production of thromboxane A2 and prostacyclin in decompensated liver disease and hepatorenal syndrome. Gastroenterology 1991; 100:1069-77.
62. Bruix J, Bosch J, Kravetz D et al. Effects of prostaglandin inhibition on systemic and hepatic hemodynamics in patients with cirrhosis of the liver. Gastroenterology 1985; 88:430-5.
63. Hamilton G, Rosza I, Hutton R et al. Portal vein prostacyclin activity in experimental portal hypertension in rats. Clin Sci 1981; 60:327-9.
64. Nadler J, Zipser RD, Horton R. The effect of adrenergic stimulation on urinary prostaglandin E2 and 6 keto PGF1alpha in man. Prostaglandins 1983; 26:519-30.
65. Hamilton G, Phing RC, Hutton RA et al. The relationship between prostacyclin activity and pressure in the portal vein. Hepatology 1982; 2:236-42.
66. Guarner C, Soriano G, Such J et al. Systemic prostacyclin in cirrhotic patients. Gastroenterology 1992; 102:303-9.
67. Ros J, Clària J, Jiménez W et al. Role of nitric oxide and prostacyclin in the control of renal perfusion in experimental cirrhosis. Hepatology 1995; 22:915-20.
68. Zipser RD, Radvan GH, Kronborg IJ et al. Urinary thromboxane B2 and prostaglandin E2 in the hepatorenal syndrome: evidence for increased vasoconstrictor and decreased vasodilator factors. Gastroenterology 1983; 84:697-703.
69. Moore K. The hepatorenal syndrome. Clin Sci 1997; 92:433-43.
70. Govindarajan S, Nast CC, Smith WL et al. Immunohistochemical distribution of renal prostaglandin endoperoxide synthase and prostacyclin synthase: diminished endoperoxide synthase in the hepatorenal syndrome. Hepatology 1987; 7:654-9.
71. Hamberg M, Svensson J, Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxide. Proc Natl Acad Sci USA 1975; 72:2994-8.
72. Abe T, Takeuchi K, Takahashi N et al. Rat kidney thromboxane receptor: molecular cloning, signal transduction, and intrarenal expression localization. J Clin Invest 1995; 96:657-64.
73. Takahashi N, Takeuchi K, Abe T et al. Immunolocalization of rat thromboxane receptor in the kidney. Endocrinology 1996; 137:5171-3.
74. Mannon RB, Coffman TM, Mannon PJ. Distribution of binding sites for thromboxane A2 in the mouse kidney. Am J Physiol 1996; 271:1131-7.
75. Bresnahan BA, Le Breton GC, Lianos EA. Localization of authentic thromboxane A2/prostaglandin H2 receptor in the rat kidney. Kidney Int 1996; 49:1207-13.
76. Asano K, Taniguchi S, Nakao A et al. Distribution of thromboxane A2 receptor mRNA along the mouse nephron segments. Biochem Biophys Res Commun 1996; 226: 613-17.
77. D'Angelo DD, Terasawa T, Carlisle SJ et al. Characterization of a rat kidney thromboxane A2 receptor: high affi nity for the agonist ligand I-BOP. Prostaglandins 1996; 52:303-16.
78. Ferrario RG, Foulkes R, Salvati P, Patrono C. Hemodynamic and tubular effects of endothelin and thromboxane in the isolated perfused rat kidney. Eur J Pharmacol 1989; 17:127-34.
79. Mene P, Dunn MJ. Contractile effects of TxA2 and endoperoxide analogues on cultured rat glomerular mesangial cells. Am J Physiol 1986; 251:F1029-F1035.
80. Roberts LJ II, Sweetman BJ, Oates JA. Metabolism of thromboxane B2 in man. Identifi cation of twenty urinary metabolites. J Biol Chem 1981; 256:8384-93.
81. Klotz TA, Cohn LS, Zipser RD. Urinary excretion of thromboxane B2 in patients with venous thromboembolic disease. Chest 1984; 85:329-35.
82. Zipser RD, Lifschitz MD. Prostaglandins and related compounds. In: Epstein M, ed. The Kidney in Liver Disease, 3rd edn. Baltimore: Williams & Wilkins, 1988; 393-416.
83. Kronborg IJ, Radvan G, Zipser RD. Urinary excretion of prostaglandins and thromboxanes in the hepatorenal syndrome. Adv Prostaglandin Thromboxane Leukot Res 1983; 11:539-46.
84. Zipser RD, Smorlesi C. Regulation of urinary thromboxane B2 in man: infl uence of urinary fl ow rate and tubular transport. Prostaglandins 1984; 27:258-71.
85. Zipser RD, Kronborg I, Rector W et al. Therapeutic trial of thromboxane synthesis inhibition in the hepatorenal syndrome. Gastroenterology 1984; 87:1228-32.
86. Laffi G, Marra F, Carloni V et al. Thromboxane-receptor blockade increases water diuresis in cirrhotic patients with ascites. Gastroenterology 1992; 103:1017-21.
87. Pinzani M, Laffi G, Meacci E et al. Intrarenal thromboxane A2 generation reduces the furosemide-induced sodium and water diuresis in cirrhosis with ascites. Gastroenterology 1988; 95:1081-7.
88. Gentilini P, Laffi G, Meacci E et al. Effects of OKY 046, a thromboxane-synthase inhibitor, on renal function in nonazotemic cirrhotic patients with ascites. Gastroenterology 1988; 94:1470-7.
89. Orning L, Kaijser L, Hammarstrom S. In vivo metabolism of LTC4 in man. Urinary excretion of LTE4. Biochem Biophys Res Commun 1985; 130:214-20.
90. Maltby N, Taylor GW, Ritter J et al. Leukotriene C4 elimination and metabolism in man. J Allergy Clin Immunol 1990; 85:3-9.
91. Huber M, Muller J, Leier I et al. Metabolism of cysteinyl leukotrienes in monkey and man. Eur J Biochem 1990; 194:309-15.
92. Gulbins E, Parekh N, Rauterberg EW et al. Cysteinyl leukotriene actions on the microcirculation of the normal and split hydronephrotic rat kidney. Eur J Clin Invest 1991; 21:184-96.
93. Barnett R, Goldwasser P, Scharshmidt LA, Schlondorff D. Effects of leukotrienes on isolated rat glomeruli and cultured mesangial cells. Am J Physiol 1986; 250:F838-F844.
94. Keppler D, Hagmann W, Rapp S et al. The relation of leukotrienes to liver injury. Hepatology 1985; 5:883-91.
95. Huber M, Kastner S, Scholmerich J et al. Analysis of cysteinyl leukotrienes in human urine: enhanced excretion in patients with liver cirrhosis and hepatorenal syndrome. Eur J Clin Invest 1989; 19:53-60.
96. Farzaneh-Far R, Moore K. Cysteinyl-leukotrienes and the liver. Prostaglandins Other Lipid Mediat 2003; 72:35-50.
97. Uemura M, Buchholz U, Kojima H et al. Cysteinyl leukotrienes in the urine of patients with liver diseases. Hepatology 1994; 20:804-12.
98. Titos E, Claria J, Bataller R et al. Hepatocyte-derived cysteinyl leukotrienes modulate vascular tone in experimental cirrhosis. Gastroenterology 2000; 119:794-805.
99. Graupera M, Garcia-Pagan JC, Titos E et al. 5-Lipoxygenase inhibition reduces intrahepatic vascular resistance of cirrhotic rat livers: a possible role of cysteinyl-leukotrienes. Gastroenterology 2002; 122:387-93.
100. Alric L, Orfi la C, Carrere N et al. Reactive oxygen intermediates and eicosanoid production by Kupffer cells and infi ltrated macrophages in acute and chronic liver injury induced in rats by CCl4. Infl ammation Res 2000; 49:700-7.
101. Sacerdoti D, Balazy M, Angeli P et al. Eicosanoid excretion in hepatic cirrhosis: predominance of 20-HETE. J Clin Invest 1997; 100:1264-70.
102. Zou A-P, Imig JD, Kaldunski M et al. Inhibition of renal vascular 20-HETE production impairs autoregulation of renal blood fl ow. Am J Physiol 1994; 266:F275-F282.
103. Zou A-P, Imig JD, Kaldunski M et al. Effect of P-450 ω-hydroxylase metabolites of arachidonic acid on tubuloglomerular feedback. Am J Physiol 1994; 266:F934-F941.
104. Imig JD, Zou A-P, Stec DE et al. Formation and actions of 20-hydroxyeicosatetraenoic acid in rat renal arterioles. Am J Physiol 1996; 270:R217-R227.
105. McGiff JC. Cytochrome P-450 metabolism of arachidonic acid. Annu Rev Pharmacol Toxicol 1991; 31:339-69.
106. Sacerdoti D, Escalante B, Abraham NG et al. Treatment with tin prevents the development of hypertension in spontaneously hypertensive rats. Science 1989; 243:388-90.
107. Carroll MA, Sala A, Dunn CE et al. Structural identifi cation of cytochrome P450-dependent arachidonate metabolites formed by rabbit medullary thick ascending limb cells. J Biol Chem 1991; 266:12306-12.
108. Prakash C, Zhang JY, Falck JR et al. 20-Hydroxyeicosatetraenoic acid is excreted as a glucuronide conjugate in human urine. Biochem Biophys Res Commun 1992; 185:728-33.
109. Sacerdoti D, Gatta A, McGiff J. Role of cytochrome P450-dependent arachidonic acid metabolites in liver physiology and pathophysiology. Prostaglandins Other Lipid Mediat 2003; 72:51-71.
110. Moore KP, Wendon J, Frazer M et al. Plasma immunoreactive endothelin in hepatorenal syndrome and liver disease. N Engl J Med 1992; 327:1774-9.
111. Morrow JD, Hill KE, Burk RF et al. A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism. Proc Natl Acad Sci USA 1990; 87:9383-7.
112. Morrow JD, Awad JA, Boss HJ et al. Non-cyclo-oxygenasederived prostanoids (F2-isoprostanes) are formed in situ on phospholipids. Proc Natl Acad Sci USA 1992;89:10721-5.
113. Roberts LJ, Morrow J. The generation and actions of isoprostanes. Biochem Biophys Acta 1997; 1345:121-35.
114. Moore KP, Roberts LS. Measurement of lipid peroxidation. Free Rad Res 1998; 28:659-71.
115. Takahashi K, Nammour TK, Fukunaga M et al. Glomerular actions of a free radical generated novel prostaglandin, 8-epiprostaglandin F2. J Clin Invest 1992; 90:136-41.
116. Fukunaga M, Makita N, Roberts LJI et al. Evidence for the existence of F2-isoprostane receptors on rat vascular smooth muscle cells. Am J Physiol 1993; 264:C1619-C1624.
117. Morrow JD, Moore KP, Awad J et al. Marked overproduction of non-cyclooxygenase derived F2-isoprostanes in the hepatorenal syndrome. J Lipid Mediators 1993; 6:417-20.
118. Morrow JD, Minton TA, Mukundan CR et al. Free radicalinduced generation of isoprostanes in vivo. J Biol Chem 1994; 269:4317-26.
119. Morrow JD, Awad JA, Wu A et al. Nonenzymatic free radical-catalyzed generation of thromboxane-like compounds (isothromboxanes) in vivo. J Biol Chem 1996; 271:23185-90.
120. Morrow JD, Harris TM, Roberts LJ II et al. Noncyclooxygenase oxidative formation of a series of novel prostaglandins: analytical ramifi cations for measurement of eicosanoids. Anal Biochem 1990; 184:1-10.
121. Holt S, Marley R, Fernando B et al. Acute cholestasisinduced renal failure: effects of antioxidant and ligands for the thromboxane A2 receptor. Kidney Int 1999; 55:271-7.
122. Guha IN, Moore K. F2-isoprostanes and the liver. Prostaglandins Other Lipid Mediat 2003; 72:73-84.
123. Plante GE, Hebert RL, Braquet P, Sirois P. Effect of platelet activating factor on renal hemodynamics and sodium excretion. Prostaglandins 1985; 30:708.
124. Caramelo C, Fernandez-Gallardo S, Santos JC et al. Increased levels of platelet activating factor in blood from patients with cirrhosis of the liver. Eur J Clin Invest 1987; 17:7-11.
125. Yang Y, Harvey SAK, Gandhi CR. Kupffer cells are a major source of increased platelet activating factor in the CCl4-induced cirrhotic rat liver. J Hepatol 2003; 39:200-7.
126. Mustafa SB, Gandhi CR, Harvey SAK et al. Endothelin stimulates platelet activating factor synthesis by cultured rat Kupffer cells. Hepatology 1995; 21:545-53.
127. Gandhi CR, Kuddus RH, Uemura T, Rao AS. Endothelin stimulates transforming growth factor-β1 and collagen synthesis in stellate cells from control but not cirrhotic rat liver. Eur J Pharmacol 2000; 406:311-18.
128. Luckey SW, Petersen DR. Activation of Kupffer cells during the course of carbon tetrachloride-induced liver injury and fi brosis in rats. Exp Mol Pathol 2001; 71:226-40.
129. Griswold JA, Beall CV, Baker CRF Jr et al. Bradykinin metabolism in the liver and lung of the rat. J Surg Res 1996; 66:12-20.
130. Abe K, Sato M, Imai Y et al. Renal kallikrein-kinin: its relation to renal prostaglandins and renin-angiotensin-aldosterone in man. Kidney Int 1981; 19:869-80.
131. MacGilchrist A, Craig KJ, Hayes PC, Cumming AD. Effect of the serine protease inhibitor, aprotinin, on systemic haemodynamics and renal function in patients with hepatic cirrhosis and ascites. Clin Sci 1994; 87:329-35.
132. Pérez-Ayuso RM, Arroyo V, Camps J et al. Renal kallikrein excretion in cirrhotics with ascites: relationship to renal hemodynamics. Hepatology 1984; 4:247-52.
133. Batkai S, Jarai Z, Wagner JA, Goparaju SK et al. Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis. Nat Med 2001; 7:827-32.
134. Pertwee RG, Ross RA. Cannabinoids receptors and their ligands. Prostaglandins Leukot Essent Fatty Acids 2002; 66:101-21.
135. Matsuda LA, Lolait SJ, Brownstein MJ et al. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990; 346:561-4.
136. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993; 365:61-5.
137. Ros J, Claria J, To-Figueras J et al. Endogenous cannabinoids: a new system involved in the homeostasis of arterial pressure in experimental cirrhosis in the rat. Gastroenterology 2002; 122:85-93.
138. Deutsch DG, Goligorsky MS, Schmid PC et al. Production and physiological actions of anandamide in the vasculature of the rat kidney. J Clin Invest 1997; 100:1538-46.
139. Fimiani C, Mattocks D, Cavani F et al. Morphine and anandamide stimulate intracellular calcium transients in human arterial endothelial cells: coupling to nitric oxide release. Cell Signal 1999; 11:189-93.